Fig. 2: Intermittent but not daily BAY1082439 treatment turns Pten-null prostate tumors to T cell-inflamed.

A A schematic illustration of treatment schedules. B FACS analyses for tumor-associated immune cells. Castrated Pten-null mice were treated with vehicle (n = 18), BAY-D (n = 7) or BAY-I (n = 11) for 4 weeks. Tumor tissues were dissociated and weighted, the numbers of tumor-associated CD45⁺, CD4⁺ and CD8⁺ T cells were measured by FACS analysis. Prostates were fixed and stained with HE, and cancer cell areas in anterior lobes were measured and fold of differences between vehicle and treatment groups were presented. Data were presented as dot plots with mean as the central lines; *p < 0.05; **p < 0.01, ***p < 0.001 by two-sided T-test. C H&E and Immunohistochemistry analyses for immune cell infiltration. Consecutive sections were stained with H&E or antibodies against CD45, CD8 and GZMb. Dashed red lines: the boundaries between cancer acini and stroma areas. The same staining was performed with 6 mice in vehicle and BAY-I cohort and 7 mice in BAY-D cohort and similar results were observed. D RNA-seq and GSEA for BAY-I responses. RNAs were extracted from BAY-I treated tumor tissues for RNA-seq analysis. GSEA analysis showed enriched IFN-γ, T cell reporter and cytokine-cytokine receptor interaction signaling pathways in BAY-I treated cohort. Statistical test was performed by GSEA. Source data and exact p values are provided in the Source Data file.